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ScienceDirectRecent advances in genome-wide association studies have
stimulated interest in the genomic prediction of disease risk,
potentially enabling individual-level risk estimates for early
intervention and improved diagnostic procedures. Here, we
review recent findings and approaches to genomic prediction
model construction and performance, then contrast the
potential benefits of such models in two complex human
diseases, aiding diagnosis in celiac disease and prospective
risk prediction for cardiovascular disease. Early indications are
that optimal application of genomic risk scores will differ
substantially for each disease depending on underlying genetic
architecture as well as current clinical and public health
practice. As costs decline, genomic profiles become common,
and popular understanding of risk and its communication
improves, genomic risk will become increasingly useful for the
individual and the clinician.
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Introduction
Heritability varies considerably between complex hu-
man diseases. Highly heritable (70% or greater) dis-
eases include autoimmune and immune-mediated
diseases, such as celiac disease (CD), type-1 diabetes
(T1D), and rheumatoid arthritis, with the strongest
associations typically localizing to the human leukocyte
antigen (HLA) region [1–7]. Other common diseases
that incur substantial mortality and morbidity world-
wide, such as cardiovascular disease (CVD), are less
heritable (50%) and usually comprise weaker genetic
associations spread over a large number of genomic
loci [8].Current Opinion in Genetics & Development 2015, 33:10–16 There has been substantial interest in leveraging the
massive amount of genome-wide genotype data now
available, mostly in the form of single nucleotide poly-
morphisms (SNPs), for the development of better risk
prediction models. Accurate genomic risk prediction has
the potential to achieve two aims: (i) prospectively iden-
tify individuals at increased risk of disease, thus informing
early interventions, and (ii) aid diagnosis for diseases
where current diagnostic approaches are imperfect.
In contrast to Mendelian disorders where causative
genetic variants have near complete penetrance,  com-
plex diseases depend on a multitude of inter-related
genetic and environmental  factors, many of which are
currently poorly understood or may indeed be stochastic
in nature. Hence, predictive genomic models for com-
plex disease do not attempt to predict particular events
(e.g. whether a specific person develops the disease or
not), rather they aim to accurately predict the probability
of an event.
The differing goals of association testing and
risk prediction
While risk prediction approaches utilize similar SNP data
to standard genome-wide association studies (GWAS), it
is important to highlight the major differences between
the two endeavors. The main aim of GWAS is reproduc-
ible detection of disease-associated loci. Typically, the
association of each SNP with disease is considered inde-
pendently of all other SNPs. Two of the main concerns of
GWAS are (i) multiple testing, that is, the inflation of false
positive rate of detection due to the large number of
statistical tests performed, and (ii) confounding of the
SNP-phenotype association by external factors, such as
population stratification, potentially leading to spurious
associations [9]. Most genotyping arrays do not necessari-
ly assay the causal variation responsible for disease,
however, due to linkage disequilibrium (LD) of geno-
typed SNPs with causal (common) SNPs, evidence for a
causal role of a locus (rather than individual SNPs) can be
established.
In contrast, the main aim of risk prediction is maximiza-
tion of predictive power (defined below), and a causal
interpretation is not strictly necessary for a good predic-
tive model. In risk prediction, the main concerns are
validity and robustness of model predictions (see
Figure 1 for a general approach to developing and vali-
dating predictive models). First and foremost is internal
validity, that is, how predictive a model is within a givenwww.sciencedirect.com
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Figure 1
Model development and internal
validation
External validation and assessment
of utility
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Typical workflow for developing and validating a genomic risk score. Building a robust genomic risk score usually requires at least two stages.
First, predictive models are developed using a set of training data and, within that data, there is an assessment of performance of all candidate
models to select the model which best fulfills the performance criteria. A common performance criterion for case/control data is the area under
the receiver-operating characteristic (ROC) curve. Typically, this is done within cross-validation, to reduce the potential problem of overfitting.
Second, once the final model has been selected it is taken forward into a validation phase, which comprises independent external data that is
used to assess predictive performance relative to both that in the training set and to other competing predictive models which were not candidate
models. Besided ROC curves, other performance measures, such as positive and negative predictive value (PPV and NPV, respectively), can also
be assessed to better understand the behavior and modes of failure for the predictive model. Finally, we may also consider the relative costs and
benefits of correct and incorrect prediction, both to individuals themselves and to health care systems as a whole.dataset. Initially, risk prediction models were based on
small numbers of SNPs, typically those identified as
genome-wide significant [10]. However, subsequent
studies have shown that predictive ability can be robustly
and reliably increased by considering all SNPs in the
model, including those that did not reach the genome-
wide significance threshold [11,12,13]. Care must be
taken to minimize the issue of overfitting, when a model
mistakes noise for signal, which typically manifests as
good performance in the training dataset but poor perfor-
mance in independent datasets [14]. It should be noted
that population stratification, usually considered an un-
welcome confounder in GWAS, may be useful in risk
prediction and may be leveraged to produce better mod-
els [15]. A reason for this is that SNPs can also serve as
proxies for shared environments, such as proximity to awww.sciencedirect.com pollutant or adherence to a particular diet. If the model is
applied to populations with similar stratification patterns
the model may be considered ‘valid’, however the mod-
el’s stratification assumptions should be clearly delineat-
ed a priori.
Methods and relative performance for
genomic prediction
Essentially all risk prediction approaches are based on the
supervised learning paradigm, where a given model is fitted
to training data containing both known inputs (also called
predictors or independent variables), in this case SNPs,
and known outputs (also called labels or dependent vari-
ables), here the binary case/control disease phenotype.
The main differences between prediction approaches
are in the assumptions about how SNPs affect risk.Current Opinion in Genetics & Development 2015, 33:10–16
12 Molecular and genetic bases of diseaseEarly methods employed polygenic scoring [16,17],
whereby the risk is based on summing the estimated
effects of a limited number of known risk alleles (such as
the log odds of disease due to each allele), or even simply
counting the number of risk alleles each person carries
ignoring their estimated effect size. Polygenic scoring
implicitly assumes that (i) all risk alleles are known
and there are only a small number of them, (ii) the
selected SNPs are independent of each other, and (iii)
the effects are additive. For the risk allele counting
approach, the implausible assumption is that the effect
size is equal across risk alleles. GWAS have shown that, in
some diseases, the assumptions of polygenic scoring are
likely overly simplistic. For example, CD has a substan-
tial number of risk alleles, both in HLA and outside of
HLA, many of which are in linkage-disequilibrium (LD)
and with different effect sizes [1–4]. The question of
additive effects remains contested, but evidence suggests
that additive effects account for the majority of genetic
effects in complex disease [18]. The simplified assump-
tions underlying polygenic scoring have been shown to
reduce the predictive power achieved in HLA-associated
diseases including CD and T1D, but not in coronary
artery disease and bipolar disorder [11,12].
Relaxing these assumptions requires more sophisticated
approaches, based on concepts first employed in breeding
value prediction in animals and plants [19–21]. Only
recently have similar approaches begun being applied
to human disease, with notable success in CD (discussed
below), T1D, and inflammatory bowel disease
[13,22,23,24–26], and to a lesser extent in other diseases
such as multiple sclerosis [27]. Commonly used models
include L1-penalized logistic regression [24,26], kernel
support-vector machines (SVM) [13], L1-penalized SVM
[11,12,22], and variants of Bayesian models employing
a genetic relatedness matrix (GRM), including linear
[23,28] and probit [15] regression.
Regardless of the model used, the same principle applies
to all: each method represents a mathematical mapping
from the SNP data (either a large subset of SNPs or all
SNPs) to the phenotype, which is then applied to new
SNP data to produce predicted phenotypes, typically in
terms of a continuous genomic risk score (GRS). The
predictive power of the GRS is quantified using measures
such as the AUC [29], the positive and negative predic-
tive values [30], or the coefficient of determination R2,
and methods such as cross-validation are employed to
combat overfitting and to ensure that the estimated
predictive power is not artificially inflated. The main
advantages of these sophisticated approaches are that
they account for inter-SNP correlations (rather than as-
suming independence), can include a large number of
SNPs in the model without overfitting, and in some cases
can account for inter-sample correlations induced by
population or familial structure.Current Opinion in Genetics & Development 2015, 33:10–16 Whether polygenic scoring methods or other more so-
phisticated models are more suitable for a given disease
depends on several factors, including the genetic archi-
tecture of the disease [12] (dictating the SNP effect size),
whether training data is available for fitting multi-SNP
models (as opposed to summary statistics), and the avail-
able sample size. Next, we highlight and contrast the
progress made by employing a range of risk prediction
methods for two diseases with starkly different aetiolo-
gies, celiac disease and cardiovascular disease.
Genomic risk scores for improved diagnosis
of celiac disease
Celiac disease (CD) is an immune-mediated disease in
response to ingestion of gluten, manifesting primarily as
villous atrophy in the small intestine. CD has a prevalence
of 1% in individuals of European ancestry [31], is highly
heritable (h2 80%), and is strongly HLA-linked [32].
From a clinical perspective, one of the main challenges
regarding CD is accurate, timely, and cost-effective diag-
nosis, as it is estimated that only 6–20% of individuals
with CD in Europe are actually diagnosed as such [32,33].
Traditional CD diagnostic pathways are based on (i)
identification of symptoms, (ii) 1st-degree family history
of CD or related autoimmune disease such as T1D, (iii)
serology, specifically transglutaminase (TG)-2 IgA and/or
deamidated gliadin peptide (DGP) IgA/IgG, and ulti-
mately (iv) small bowel biopsy to detect villous atrophy
and confirm the diagnosis. Current approaches have sev-
eral drawbacks. First, both serology and biopsy require
active gluten intake prior to the test. Second, serology
may exhibit substantial variability [34] and may not
capture seronegative cases. Third, biopsy is costly, time
consuming, and inconvenient to the patient. By avoiding
biopsies in individuals at low risk or alternatively, in
individuals where CD can be confidently established
via other means, there is potential for improved patient
care together with cost savings to both the patient and the
health system.
CD is strongly dependent on particular HLA heterodi-
mers (DQ2, DQ8, and to a lesser extent DQ7), which are
encoded by specific haplotypes of HLA-DQA1 and HLA-
DQB1. Virtually all (>99%) CD individuals are ‘positive’
(have at least one of the risk alleles), however being HLA
positive is only weakly predictive of the absolute risk of
disease, as the population prevalence of these heterodi-
mers is high (40–56%) [35] relative to the prevalence of
CD (1%).
Recognizing the strong HLA dependence, recent clinical
guidelines for CD diagnosis [36,37] recommend screen-
ing for the DQ2/DQ8 heterodimers in specific clinical
scenarios, particularly for excluding CD in individuals
with uncertain diagnosis and in 1st-degree relatives of
individuals with T1D and related diseases, but not forwww.sciencedirect.com
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established that different HLA heterodimers carry dif-
ferent risks of CD, with DQ2.5 conferring the highest
risk, there is no consensus around what the actual risk is
and, consequently, HLA-based screening remains binary:
positive/negative for HLA risk heterodimers.
Current genetic risk prediction methods in CD diagnosis
aim to go beyond negative screening and toward better
positive diagnosis of individuals at increased risk. Hence,
early risk models stratified individuals by their HLA-
associated risk (low/medium/high) rather than HLA pres-
ence/absence [38]. Subsequent polygenic models in-
creased the number of SNPs in the model, including
non-HLA and fine-mapping (Immunochip) variants, and
used SNP-specific weights derived from GWAS instead
of equal weighting, increasing the area under the receiv-
er-operating curve (AUC) from 0.82 to 0.85 [10]. Fur-
ther improvements were achieved through models which
consider all SNPs regardless of their marginal association
p-value and account for inter-SNP correlations, including
an L1-penalized SVM [11] and MultiBLUP [23], lead-
ing to AUCs of up to 0.90 in external validation.
Genetic testing is unique: it is independent of gluten
consumption, it exhibits less technical variability than
serology, and (somatic variation aside) genotypes do not
change over the lifetime. Further, the main advantage of
GRS-based approaches over binary HLA status is that a
GRS is based on an explicit statistical model, allowing
prediction of risk as a continuous score rather than sus-
ceptible/not-susceptible, where an appropriate threshold
for the score can be determined by a cost-benefit analysis
considering both the clinical and financial consequences
of false positives and false negatives. Ultimately, genetic
testing may only ascertain an individual’s susceptibility to
CD. It is likely that models that incorporate all available
information, including genomic variation, serology, and
other molecular phenotypes will lead to improved diag-
nosis of CD.
Genomic risk scores for prospective risk
prediction in cardiovascular disease
Cardiovascular diseases (CVD) are a heterogeneous
group of diseases specific to the heart and blood vessels;
they include manifestations such as coronary artery dis-
ease, myocardial infarction, heart failure, stroke, and
peripheral artery disease, among others. CVD differ
substantially from autoimmune disease as they tend to
develop over a long period of time (typically decades),
are only moderately heritable (50%), and are typically
based on an infinitesimal genetic architecture with small
effect sizes spread across many loci [8,39]. With CVD, a
key clinical issue pertaining to risk prediction is not
diagnosis as such but high-risk stratification at the earliest
feasible stage to enable efficient interventions. Large
prospective longitudinal cohorts such as the Framinghamwww.sciencedirect.com cohort have enabled identification and quantification of
how potential CVD risk factors, such as an individual’s
sex, age, high density and total cholesterol levels, sys-
tolic blood pressure, and smoking status, all contribute to
future development of CVD [40]. Risk scores using such
factors provide the ability to prospectively identify
which individuals will achieve a clinically-relevant level
risk of CVD within a given time frame. Those high-risk
individuals would be prioritized for interventions, such
as diet, exercise and statin medication [41,42]. Current
clinical scores achieve moderately high C-index (con-
cordance) exceeding 0.8 over time horizons of 5–10 years
across the entire population, however, there are substan-
tial subgroups of individuals with low short-term risk
who may nonetheless have high long-term risks of CVD
[43].
There has been substantial interest in further improving
predictive power by incorporating genomic risk scores for
CVD into existing clinical risk scores. While the latest
estimates of heritability explained by common SNPs are
modest (10%), even small improvements in predictive
power may translate to large numbers in absolute terms
due its immense burden in terms of mortality and mor-
bidity worldwide [44]. Critically, genomic risk may still be
informative without any overt clinical symptoms or ele-
vated clinical risk factors.
In contrast to case/control studies, most studies explor-
ing GRSs for CVD have employed survival models due
to the longitudinal nature of the data and the need to
deal with censored observations. Unlike the sophisticat-
ed approaches employed for CD and other case/control
data, the CVD genomic scores have mostly been derived
using the polygenic score approach, namely, adding the
contributions of a small number of genome-wide signifi-
cant SNPs identified in GWAS or meta-analyses [8].
These genomic scores are then often combined with
existing clinical risk factors [45,46,47–52] as the pre-
dictive power of the GRS itself is low compared with the
clinical variables but is typically independent of them.
Despite the fact that the genomic risk scores proposed so
far have been significantly associated with time to CVD
in most studies, the combined clinical and genomic
scores have achieved only modest improvements in
predictive power.
Despite apparently small improvements in prediction
close to a diagnosis or event, the lifetime cumulative
effects of a GRS may be substantial nonetheless: a recent
12 SNP GRS for atrial fibrillation demonstrated a two-fold
increase of cumulative risk from 6% to 12% at 15 years
since baseline (with C-index increasing from 0.735 to
0.738) [50]. A similar GRS based on 32 SNPs associated
with blood pressure was found to be significantly associ-
ated with other CVD outcomes including coronary heart
disease and ischemic stroke [47], indicating some sharedCurrent Opinion in Genetics & Development 2015, 33:10–16
14 Molecular and genetic bases of diseasegenetic basis for the two conditions and suggesting that
such genomic risk scores could be useful across a wide
range of cardiovascular diseases.
It is likely that due to the genetic architecture of CVD,
substantially larger sample sizes will be necessary to yield
useful predictive risk scores [53]. Furthermore, reliance
on simple methods for SNP selection and utilizing only
small numbers of SNPs have likely reduced the predic-
tive power of models proposed so far, and employing
more sophisticated models may improve predictive pow-
er. As risk prediction improves, two issues will become
increasingly important: (i) communication of genetic risk
to individuals so that interventions such as diet and
exercise are undertaken, and (ii) maximizing the effec-
tiveness of the intervention for those at high genetic risk.
For (i), research into how communication of genetic risk
from multiple variants changes behavior is still urgently
needed for complex diseases [54]. For (ii), diseases with
known interventions are likely to be the first to benefit
from genetic risk prediction, such as the effect of lifestyle
change on cumulative risk of type-2 diabetes for those
with high-risk TCF7L2 alleles [55].
Conclusions
The main aims of genomic risk prediction are (i) to
accurately quantify individual risk early in pathogenesis
so that preventative measures may be taken, and (ii) to
better diagnose individuals when established diagnostic
procedures are not sufficiently informative. In both cases,
the genomic risk only represents the heritable component
of risk, and more accurate prediction will likely require
integration with existing and as yet unknown risk factors,
be they genetic, molecular, environmental, or otherwise.
The decreasing costs of genotyping and high-throughput
sequencing together with rapidly improving genomic risk
prediction models, particularly for autoimmune and car-
diovascular diseases, raise the possibility of clinically
informative risk prediction both early in pathogenesis
and at point-of-care, ultimately improving clinical out-
comes while reducing costs.
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